RxDoctor Payments Data

Abdullattief Sulieman, MD

General Practice · Milwaukee, WINPI 1881864197

Payments from drug & device makers

$1,672in general payments, 2019–2025

Across 69 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$614
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$354
  • Genentech USA, Inc.$130
  • Pfizer$85
  • Merck$75
  • Melinta Therapeutics, LLC$72
  • plus $343 from 11 others

What the payments were for

  • Food & beverage$1,65499%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,672 in reported general payments places this provider in the 90th percentile of 1,554 general practice providers in Wisconsin.

See all general practice providers in Wisconsin

Medicare billing

Part B allowed, 2024
$21,631
Medicare patients
34
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin30$30,249
LinzessLinaclotide29$20,673
JanumetSitagliptin Phos/Metformin Hcl33$18,769
TrulicityDulaglutide16$16,441
JardianceEmpagliflozin18$14,553
FarxigaDapagliflozin Propanediol18$11,331
Jentadueto XrLinagliptin/Metformin Hcl11$6,868
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl55$4,998
SymbicortBudesonide/Formoterol Fumarate20$4,714
Breo ElliptaFluticasone/Vilanterol11$4,460
Insulin Lispro Kwikpen U-100Insulin Lispro11$2,919
Albuterol Sulfate HfaAlbuterol Sulfate113$1,964
Omega-3 Acid Ethyl Esters15$1,884
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,819
Gabapentin137$1,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet$75$18,76933 claims
AstraZenecaFarxiga, Symbicort$614$16,04438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,554 general practice providers in Wisconsin.

Other general practice in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →